Biotech Replimune Group, Inc. , which conducts research and cancer treatment studies using oncolytic viruses, picked up a sell-side bull Tuesday. BMO Capital Markets analyst Do Kim initiated coverage of Replimune Group with an Outperform rating and $31 price target. Source